TVGN Tevogen Bio Holdings Inc.
Q3 2025 10-Q
Filed: Nov 14, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Tevogen Bio Holdings Inc. (TVGN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 14, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: Nasdaq non-compliance due to Common Stock closing bid below $1.00 for 30+ days as of Sept 23, 2025
- • Material update: Nasdaq gives 180 days to regain $1.00 bid compliance, or risk delisting by March 23, 2026
Quarterly Financial SummaryXBRL
Net Income
-$6M
ROE
73.2%
Total Assets
$4M
Source: XBRL data from Tevogen Bio Holdings Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.